Related references
Note: Only part of the references are listed.ABT-335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans
Tong Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Superior Benefit of Aggressive Lipid-Lowering Therapy for High-Risk Patients Using Statins: the SUBARU Study - More Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals with Rosuvastatin Therapy than with Atorvastatin Therapy
Masahiko Kurabayashi et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2008)
Liver toxicity of rosuvastatin therapy
Giuseppe Famularo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and Fenofibrate
JH Ireland et al.
ANNALS OF INTERNAL MEDICINE (2005)
The effect of erythromycin on the pharmacokinetics of rosuvastatin
KJ Cooper et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Share Paper
